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Background: Despite aggressive treatment with radiation therapy and concurrent adjuvant temozolomide (TMZ),
glioblastoma multiform (GBM) still has a dismal prognosis. We aimed to identify strategies to improve the
therapeutic outcome of combined radiotherapy and TMZ in GBM by targeting pro-survival signaling from the
epidermal growth factor receptor (EGFR).
Methods: Glioma cell lines U251, T98G were used. Colony formation, DNA damage repair, mode of cell death,
invasion, migration and vasculogenic mimicry as well as protein expression were determined.
Results: U251 cells showing a low level of methyl guanine transferase (MGMT) were highly responsive to the
radiosensitizing effect of TMZ compared to T98G cells having a high level of MGMT. Treatment with a dual inhibitor
of Class I PI3K/mTOR, PI103; a HSP90 inhibitor, 17-DMAG; or a HDAC inhibitor, LBH589, further increased the
cytotoxic effect of radiation therapy plus TMZ in U251 cells than in T98G cells. However, treatment with a mTOR
inhibitor, rapamycin, did not discernibly potentiate the radiosensitizing effect of TMZ in either cell line. The
mechanism of enhanced radiosensitizing effects of TMZ was multifactorial, involving impaired DNA damage repair,
induction of autophagy or apoptosis, and reversion of EMT (epithelial-mesenchymal transition).
Conclusions: Our results suggest possible strategies for counteracting the pro-survival signaling from EGFR to
improve the therapeutic outcome of combined radiotherapy and TMZ for high-grade gliomas.
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Glioblastoma multiforme (GBM) is the most common
malignant primary brain tumor in adults and is among the
most aggressive of all human tumors. Recent data from a
randomized phase III clinical trial by the European
Organization for Research and Treatment of Cancer/
National Cancer Institute of Canada (EORTC 26981-
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reproduction in any medium, provided the ortemozolomide (TMZ) combined with radiation therapy
results in significantly improved outcome in patients with
GBM. However, despite this improvement the majority of
patients with GBM relapse soon after treatment and the
2-year survival rate is only 26% [1].
Methylguanyl methyltransferease (MGMT) was the
first molecular marker to serve as both a prognostic fac-
tor and a target for personalized therapy [2], and thera-
peutic resistance in MGMT-unmethylated tumors has
emerged as an important clinical issue. Several other
molecular biomarkers that regulate tumor growth, pro-
liferation, and survival are being investigated as potential
targets in the management of GBM. The Cancer Gen-
ome Atlas Research Network for GBM showed the roled. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of the phosphatidylinositol-3-OH kinase regulatory sub-
unit gene PIK3R1, and provides a network view of the
pathways altered in the development of GBM [2]. One
of the most common genetic alterations in primary
GBM is over-expression of epidermal growth factor re-
ceptor (EGFR), which is observed in more than 50% of
GBMs. Over-expression of EGFR and/or its constitu-
tively activated variant EGFRvIII is associated with
tumorigenesis and more aggressive phenotypes, such as,
invasiveness and therapeutic resistance in GBM [3]. Pre-
clinical data suggest that over-expression of EGFR con-
fers radiation resistance on malignant glioma and that
blocking EGFR restores radiosensitivity. However, the re-
sults of EGFR-targeted therapy trials for GBM, including
gefitinib and erlotinib, have been disappointing due to
diverse mechanisms of therapeutic resistance [4]. Emer-
ging evidence indicates an important role that PTEN plays
in predicting GBM response to EGFR-targeted therapy [5].
Aberrant PI3K/Akt/mTOR pathway has been shown to
contribute to the resistant phenotype in glioma. Therefore,
the EGFR/PI3K/Akt/mTOR pathway is regarded as the
most amenable pathway to pharmacologic intervention in
glioma [6]. We previously demonstrated an important role
of PI3K-Akt-mTOR signaling in the radiation response
[7]. In the present study, we evaluated the effect of target-
ing PI3K-Akt-mTOR signaling pathway, to identify effect-
ive strategies to improve therapeutic outcome when
radiotherapy and TMZ are used concurrently to treat
GBM.
The molecular chaperone HSP90 is known to stabilize
Akt and oncogenic forms of mutant EGFR, both of
which contribute to the growth of a variety of cancers
including gliomas [8]. We previously reported that
HDAC inhibitors potentiate radiation-induced cell kill-
ing in a panel of human cancer cells with activated
EGFR signaling through diverse mechanisms [9]. A re-
cent study also showed that HDAC inhibitors induced
acetylation of HSP90, resulting in disruption of HSP90
chaperone function with EGFR and other oncogenic
proteins in NSCLC [10]. Therefore, we also tested the
effect of ligand-independent modulation using an HSP90
inhibitor and epigenetic modulation using a histone dea-
cetylase (HDAC) inhibitor, focusing on targeting pro-
survival signaling from EGFR. Additionally, the signaling
cascades downstream of aberrant EGFR activation con-
tribute to invasive phenotype in GBM and a mesenchy-
mal feature of GBM is considered to be a major
therapeutic obstacle for GBM treatment [11]. The recent
recognition of mesenchymal change in glioblastoma and
its association with more aggressive clinical phenotypes
suggests that mechanisms that promote epithelial to
mesenchymal transition (EMT) may be of great clinical
relevance in GBM [12,13]. Thus, we also investigatedinhibitory effects of these inhibitors in combination with
TMZ on invasion, migration and vasculogenic mimicry
formation of glioma cells.
Methods
Cell culture
The human GBM cell lines U251, U87, and T98G used
in this study were obtained from the American Type
Culture Collection (ATCC). All ATCC cell lines were au-
thenticated by the company routine Cell Biology Pro-
gram and were used within 6 months of receipt for this
study. Cells were maintained and cultured according to
standard techniques at 37°C in 5% (v/v) CO2 using cul-
ture medium recommended by the supplier. In all exper-
iments, the different cell populations were first cultured
in DMEM media containing 10% fetal bovine serum.
Pharmacologic inhibitors
TMZ (Schering-Plough, Kenilworth, NJ, USA) was pre-
pared by dissolving the drug in dimethyl sulfoxide
(Sigma-Aldrich, St, Louis, MO, USA). PI103 (a pyridi-
nylfuranopyrimidine inhibitor and a dual inhibitor of
Class I PI3K and mTOR) and 17-Desmethoxy-17-N, N-
dimethylaminoethylamino-geldanamycin, HCl, 17-N, N-
Dimethylaminoethylamino-17-demethoxy-geldanamycin,
HCl (17-DMAG), were obtained from Calbiochem®
(Darmstadt, Germany). Rapamycin was obtained from
Cell Signaling Technology, Inc (Beverly, MA, USA).
Panobinostat (LBH589) was obtained from Selleck Che-
micals LLC (Houston, TX, USA). Inhibitors were pre-
pared as concentrated stock solutions in DMSO, stored
at −20°C, and diluted in culture medium at the time of
use. Control cells were treated with medium containing
the same concentration of the drug carrier, DMSO.
RNA interference
Two × 105 cells were plated into each well of six well tis-
sue culture plates. The next day (when the cells were
40–50% confluent), the culture medium was changed
with antibiotics free medium. EGFR siRNA (5′- AAG
AUC AUA AUU CCU CUG C -3′) was 19 nucleotides
and nonspecific siRNA with similar GC content to the
EGFR siRNA was used for control (Bioneer®, Daejeon,
Korea).
Each EGFR siRNA and nonspecific control siRNA in
reduced serum medium (OPTIMEM, Life Technologies)
was transfected into cell using Lipofectamine 2000 (Invi-
trogen®, Carlsbad, CA) according to the manufacturer’s
protocol. Forty-eight hours following transfection, cells
were trypsinized, diluted to the appropriate cell density
and plated in dishes for colony formation. Lysates from
these cultures were screened for protein expression by
Western blot analysis.
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GBM cells were seeded into 6 well plates in 10% fetal bo-
vine serum and on the first day of treatment the media
were replaced with vehicle control or each drug with or
without TMZ in DMEM media without fetal bovine
serum. The media treated with drugs were replaced with
DMEM media containing 10% fetal bovine serum after
24 hr. A specified number of cells were seeded into each
well of 6-well culture plates. Cells were irradiated with
6MV X-ray from a linear accelerator (Clinac 6/100, Varian
Medical Systems, Palo Alto, CA) at a dose rate of 2.46
Gy/min. As indicated, prior to irradiation cells were
treated with TMZ (25 μM) with or without the inhibitors
PI103 (0.4 μM), rapamycin (100 nM), 17-DMAG (25 nM),
and LBH589 (20 nM) followed by incubation at 37°C for
10 to 14 days. Colonies were fixed with methanol and
stained with 0.5% crystal violet; the number of colonies
containing at least 50 cells was determined and surviving
fraction was calculated. Radiation survival data were fitted
to a linear-quadratic model using Kaleidagraph version
3.51 (Synergy Software, Reading, PA). We performed three
independent experiments and each point on the survival
curves represents the mean surviving fraction from tripli-
cates. Sensitizer enhancement ratio (SER) was calculated
as the ratio of the isoeffective dose at surviving fraction
0.5 and surviving fraction 0.05 in the absence of each in-
hibitor to that in the presence of each inhibitor.
Western blot analysis
Cells were washed, scraped, and resuspended in lysis buf-
fer (iNtRON Biotechnology, Seoul, Korea). Proteins were
solubilized by sonication and equal amounts of protein
were separated by SDS-PAGE and electroblotted onto
polyvinylidene difluoride membranes (Millipore Corp.,
Bedford, MA, USA). Membranes were blocked in PBS
containing 0.1% Tween 20 and 5% powdered milk and
probed with primary antibody directed against p-EGFR
(Tyr1068), p-Akt (Ser473), p-ERK (Tyr202/204), p-
p70S6K (Thr421/Ser424), HSP70, HSP90, DNA-PKs
(Thr2609), Rad51, caspase-3, LC3, MMP-2, E-cadherin,
and EphA2 (Cell Signaling Technology, Inc.) at 1:1000 di-
lutions. Primary antibodies against MGMT (Abcam, Cam-
bridge, UK) and Acetyl Histone H3 (Millipore Corp.) were
used at a dilution of 1:1000. Antibodies against VEGF and
β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
were used at dilutions of 1:500 and 1:5000, respectively.
Membranes were washed and incubated with peroxidase-
conjugated goat anti-rabbit or anti-mouse IgG secondary
antibody (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) at a dilution of 1:5000.
Immunocytochemistry
Cells were seeded on chamber slides. At specified times
after treatment, cells were fixed in 4% paraformaldehyde,and permeablized in methanol for 20 min. Cells were
subsequently washed and blocked in PBS containing 2%
bovine serum albumin for 1 h. Primary antibody against
γH2AX (Cell Signaling Technology) was applied to the
cells and incubated overnight. Secondary FITC anti-
rabbit antibody (Molecular Probes, Eugene, OR, USA)
was applied and incubated for 2 h. DAPI nuclear counter
stain was applied at 1 μg/mL for 5 min. Slides were ex-
amined on an Axio Scope.A1 Imager fluorescent micro-
scope. Images were captured and acquired using
AxioCam MRc5 and acquisition software AxioVision
v.4.4 (Carl Zeiss, Gottingen, Germany).
Caspase-3/7 assay
Cells (3 × 104 per well) were seeded in a 96-well plate
with 200 μl culture medium. Cells were treated with
TMZ with or without each inhibitor prior to irradiation.
Casapse-3/7 activity was measured as per manufacturer’s
instructions (Invitrogen).
Annexin V-FITC/Propidium Iodide (PI) double-staining
Apoptosis was demonstrated using Annexin V-FITC/
Propidium Iodide (PI) double-staining. Cells were seeded
in 8-well chamber slides, treated with each inhibitor
with or without TMZ prior to irradiation and double-
stained with Annexin V-FITC and propidium iodide ac-
cording to the manufacturer’s instruction (BD) and then
analyzed under a fluorescence microscope (Carl Zeiss).
Cellular senescence-associated β-galactosidase assay
Cellular senescence was examined by detecting the activ-
ity of β-galactosidase. Tumor cells were seeded in 8-well
chamber slides, treated with reagents prior to irradiation,
and then stained using Senescence β-Galactosidase
Staining Kit (Cell Signaling Technology) according to
the manufacturer’s instruction. Cells were examined
using a light microscope.
Modified Boyden chamber assay
Cell invasion was measured using a Transwell system
(Corning, Rochester, NY, USA) that allows cells migrate
through 8-μm pores in polycarbonate membranes. In-
serts containing cells were placed in 24-well plates
(Corning) in starvation medium. Cells were trypsinized
and resuspended, and an aliquot of 104 cells was added
to the upper chamber. After 24 h, inserts were fixed in
methanol and stained with 1% crystal violet.
Wound healing assay
Cells were grown to confluence in 6-well plates (Sonic-
Seal Slide; Nalge Nunc, Rochester, NY, USA) and then
starved as described above. Each well was divided into a
2 × 3 grid. Using a 1-mL pipette tip, a line was scratched
in each hemisphere of the well to wound the cells and
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ages were taken of the intersections of the linear cell
wound and each grid line. The pictures of same area
were taken immediately after a wound was inflicted to
the cell and at time point 24 hrs. Migration rate was es-
timated from the distance that the cells moved, as deter-
mined microscopically. The distances between the edges
of the wound were measured by using Image J software.
The sixty measurements were taken for each experimen-
tal condition. The degree of mobility is expressed as per-
cent of wound closure as compared with the zero time
point. Migration rates were calculated using the follow-
ing equation: (initial distance-final distance/initial dis-
tance) × 100.
Vasculogenic mimicry formation assay
Vasculogenic mimicry (VM) formation assay was per-
formed using a commercialized Matrigel assay kit (BD
Biosciences, France). 200 μL ECM Matrigel was dropped
in 48-well tissue culture plates and then incubated at
37°C for 2 hr. Cells were treated with TMZ (25 μM) with
or without the inhibitors PI103 (0.4 μM), rapamycin
(100 nM), 17-DMAG (25 nM), and LBH589 (20 nM)
and then seeded onto the coated plate. After growth for
24 hr on the plate, VM formation was assessed using an
inverted microscope.
Statistical analysis
These results are expressed as the mean ± SD of three
independent experiments. Data from these experiments
were analyzed by Student’s t test (SPSS12.0 software).
Significant differences were established at P < 0.05.
Results
Specific inhibition of EGFR using RNA interference
First, we evaluated p-EGFR, MGMT expression levels in
a panel of glioma cell lines. U251 and T98G showed
similar levels of p-EGFR expression. U251 and U87 cells
showed low level of MGMT, as previously described [14]
which might highlight a high level of MGMT promotor
methylation, compared with T98G (Figure 1A). To de-
termine the effect of targeting EGFR signaling during
the radiation response, U251 cells and T98G cells were
transfected with either EGFR-specific siRNA or nonspe-
cific siRNA. Specific inhibition of EGFR did not attenu-
ate signaling through downstream mechanisms such as
p-Akt, p-ERK (Figure 1B), and did not result in signifi-
cant radiosensitization (sensitizer enhancement ratio at
surviving fraction of 0.5 [SER0.5], 1.0) (Figure 1C).
Targeting PI3K-Akt-mTOR pathway
We tried to determine whether inhibition of these tar-
gets would further increase the radiosensitizing effect of
TMZ. Since inhibition of mTOR is a way to avoidpossible side effects associated with inhibition of PI3K-
Akt, we tested whether rapamycin would cause radiosen-
sitivity in glioma cells. Pretreatment with rapamycin
(0.1 μM) caused a dramatic reduction in the level of p-
p70S6K, but did not discernibly potentiate the radiosen-
sitizing effect of TMZ in either cell line (p > 0.05 for
U251 and T98 G Cells, Figure 2A). As shown in
Figure 2B, PI103, a dual inhibitor of class I PI3K and
mTOR, markedly reduced p-Akt and p-p70S6K protein
levels, and effectively potentiated the radiosensitizing ef-
fect of TMZ in both cell lines (p < 0.05 for U251 and
T98G cells). Similar results were seen with U87 cells
(Additional file 1: Figure S1A). Additional file 1: Tables
S1 and Additional file 1: Table S2 show the sensitizer en-
hancement ratio (SER) for each inhibitor alone and com-
bined with TMZ in U251, T98G, and U87 cells. PTEN-
mutant U251 cells showed higher radiosensitizing effect
of PI103 than that of T98G which has PTEN-wild type
(SER0.5 1.41 vs. 1.26).
Ligand-independent modulation using HSP90 inhibitor
As shown in Figure 2C, pretreatment with a HSP90 in-
hibitor, 17-DMAG (25 nM), increased expression of
HSP70 and attenuated levels of its client proteins, p-
EGFR and p-Akt. 17-DMAG effectively potentiated the
radiosensitizing effect of TMZ (p < 0.05 for U251 cells).
This effect was more pronounced in U251 cells than in
T98G cells at the higher radiation doses (Additional file
1: Tables S1 and Additional file 1: Table S2). Similar re-
sults were seen with U87 cells (Additional file 1: Figure
S1B).
Epigenetic modulation using HDAC inhibitor
As shown in Figure 2D, pretreatment with a HDAC in-
hibitor, LBH589 (20 nM), induced acetylation of histone
H3, leading to acetylation of HSP90 and down-
regulation of its client proteins p-EGFR and p-Akt.
LBH589 effectively potentiated the radiosensitizing effect
of TMZ (p < 0.05 for U251 cells). This effect was more
pronounced in U251 cells than in T98G cells and oc-
curred at higher radiation doses (Additional file 1: Tables
S1 and Additional file 1: Table S2).
Impairment of DNA damage repair following irradiation
U251 cells were pretreated with the indicated inhibitors
plus TMZ before assessment of γH2AX foci formation.
Mock-treated control cells were analyzed 6 h after ir-
radiation with 6 Gy. Pretreatment of U251 cells with the
dual inhibitor PI103, the HSP90 inhibitor 17-DMAG, or
the HDAC inhibitor LBH589 combined with TMZ
caused marked prolongation of radiation-induced
γH2AX foci formation 6 h after irradiation with 6 Gy
(Figure 3A), indicating delayed DNA damage repair. Pre-


















































Figure 1 Specific inhibition of EGFR does not result in radiosensitization of U251 and T98G cells. (A) Forty-eight hours after serum
starvation, western blot analysis showed low levels of MGMT expression in U87 and U251 cells, and a high level of MGMT expression in T98G cells.
U251 and T98G showed similar levels of p-EGFR expression. (B) Western blot analysis of U251 and T98G cells transfected with EGFR-specific or
nonspecific siRNA. (C) Cells were plated for colony formation assay 48 h after transfection with EGFR-specific or nonspecific siRNA and irradiated
as indicated. Points on survival curves represent mean surviving fractions from minimum three experiments performed in triplicate.
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PK (Figure 3B).
Mode of cell death
Annexin V-FITC/PI double staining and Caspase 3/7
assay method were employed to examine apoptotic cell
death. Annexin-V-FITC staining targets the membranes
of apoptotic cells, showing green fluorescence, while PI
staining targets the nuclei of apoptotic cells, showing
red fluorescence. As shown in Figure 4A, the combined
treatment of TMZ with 17-DMAG or LBH589 showed
fluorescent green cell membranes and fluorescent red
nuclei. Additionally, treatment of TMZ with 17-DMAG
or LBH589 increased cleaved caspase3 expression and
caspase-3/7 activity within 24 h after combination treat-
ment on U251 cells (Figure 4B, P < 0.05). Pretreatment
with TMZ combined with rapamycin or PI103 increased
punctate fluorescence or lysosomal localization of Lyso-
Tracker in U251 cells at 24 h (Figure 4C). To furtherelucidate the mechanism underlying autophagy in U251
cells, we examined the effect of the combination treat-
ment of each inhibitor with or without TMZ on the con-
version of microtubule-associated protein light chain
(LC3). Treatment with rapamycin or PI103 in the pres-
ence or absence of TMZ increased LC3–II (16 kDa) ex-
pression in U251 cells at 24 h after each combined
treatment (Figure 4D). Senescence was examined by de-
tecting the activity of β-galactosidase and no discernable
change was detected in U251 cultures within 7 days after
each treatment (Additional file 1: Figure S2).
The effect on invasion, migration and vasculogenic
mimicry of glioma cells
Invasion, and migration are key processes of tumor pro-
gression and are tightly linked to tumor recurrence and
therapeutic resistance in glioblastoma [8]. Radiation
(6 Gy) and/or TMZ treatment did not cause the inhib-






























Figure 2 Targeting PI3K-Akt-mTOR signaling. (A) U251 and T98G cells were pretreated with rapamycin (RPM) plus TMZ for 24 h and
subjected to western blot analysis using the indicated antibodies. Pretreatment with rapamycin (100 nM) plus TMZ (25 μM) did not have a
synergistic radiosensitizing effect compared to TMZ alone treatment on U251 and T98G cells. (B) U251 and T98G cells were pretreated with a
dual inhibitor of class I PI3K and mTOR signaling, PI103 (0.4 μM), and TMZ (25 μM) for 24 h. PI103 effectively enhanced the radiosensitizing effect
of TMZ in both U251 and T98G cells. (C) U251 and T98G cells were pretreated with the HSP90 inhibitor 17-DMAG (25nM) and TMZ (25 μM) for
24 h. 17-DMAG enhanced the radiosensitizing effect of TMZ in U251 and T98G cells. (D) U251 and T98G cells were pretreated with TMZ (25 μM)
and LBH589 (20 nM) for 24 h. LBH589 effectively potentiated the radiosensitizing effect of TMZ. Points on survival curves represent mean surviving
fractions from minimum three experiments performed in triplicate.
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Figure 3 Impairment of DNA damage repair following irradiation. (A) U251 cells were pretreated with the indicated inhibitors plus TMZ
before assessment of γH2AX foci formation. Mock-treated control cells were analyzed 6 h after irradiation with 6 Gy. Pretreatment of U251 cells
with the dual inhibitor PI103, the HSP90 inhibitor 17-DMAG, or the HDAC inhibitor LBH589 plus TMZ caused marked prolongation of radiation-
induced γH2AX foci formation 6 h after 6Gy irradiation. (B) Pretreatment of U251 cells with TMZ combined with PI103, 17-DMAG, or LBH589
attenuated p-DNA-PK expression.
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DMAG or LBH589 markedly inhibited the ability of mi-
gration and invasion of U251 glioma cells (Figure 5A, B,
P < 0.05).
Vasculogenic mimicry (VM) is known as non-
endothelial tumor cell-lined microvascular channels in
aggressive tumors and is associated with aggressive and
invasive nature of gliomas [13]. Since VM has a totally
different structure from endothelium-dependent vessels,
traditional anti-vascular therapies aiming at endothelialcells have no remarkable effects on malignant tumor
with VM [15]. To evaluate the inhibitory effect of each
treatment on VM, we performed VM formation assay
using U251 glioma cells. PI103 or 17-DMAG or LBH589
combined with radiation and/or TMZ significantly im-
paired VM formation of U251 glioma cells compared
with TMZ alone treatment (Figure 5C).
Consistent with the reduction of invasion, migration
and VM formation, the combination treatment of TMZ
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Figure 4 (See legend on next page.)
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Figure 4 Mode of cell death. (A) Annexin-V-FITC/PI double staining images of each treatment at 24 h. Annexin-V-FITC staining targets the
membranes of apoptotic cells, showing green fluorescence, while PI staining targets the nuclei of apoptotic cells, showing red fluorescence. The
combination treatment of TMZ with 17-DMAG or LBH589 increased green and red fluorescence on U251 cells. (B) The combination treatment of
TMZ with 17-DMAG or LBH589 increased caspase-3/7 activity and cleaved caspase3 expression within 24 h after combination treatment on U251
cells. Data are presented as the mean ± SD of three experiments. *P < 0.05 versus IR. †P < 0.05 versus IR and TMZ. (C) Pretreatment of U251 cells
with TMZ combined with rapamycin or PI103 increased punctate fluorescence or lysosomal localization of LysoTracker at 24 h. (D) Treatment with
rapamycin or PI103 with or without TMZ increased LC3–II (16 kDa) expression in U251 cells at 24 h after each combined treatment. Each experiment
was repeated three times with similar results.
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(VEGF), matrix metalloproteinase (MMP) 2 and EphA2.
In contrast, the treatment of TMZ with PI103 or 17-
DMAG or LBH589 led up-regulation of epithelial marker
E-cadherin (Figure 5D). As shown in Figure 5E, abundant
staining for EphA2 was observed in control, TMZ, and
rapamycin with or without TMZ. In contrast, the level of
EphA2 was considerably lower when the cells were treated
by TMZ with PI103 or 17-DMAG or LBH589.
Discussion
The current standard of care for malignant glioma is ini-
tial treatment with radiation therapy combined with
TMZ; however, malignant gliomas usually recur with a
median time to progression of approximately 7 months
[1]. Two decades of molecular studies have identified
important genetic events such as dysregulation of
growth factor signaling via amplification or mutation of
receptor tyrosine kinase genes; activation of PI3K path-
way; and inactivation of p53 and Rb tumor suppressor
pathways [2]. In this study, we tried to identify the po-
tential targets for counteracting the pro-survival signal-
ing implicated in radioresistance of malignant glioma
cells and to get insight into potential strategies to im-
prove the therapeutic outcome of radiotherapy and
TMZ in the management of GBM.
Inhibition of signal transduction pathways may provide
the basis for a new paradigm of GBM therapy, based on
the fact that most human gliomas exhibit aberrant acti-
vation of a pro-survival/pro-growth signaling network.
EGFR is one of the most attractive therapeutic targets in
GBM since the gene is amplified and over-expressed in
approximately 40% of primary GBMs, especially those of
the classical subtype. Nearly half of tumors with EGFR
amplification also express a constitutively active EGFR
mutant, EGF variant VIII (EGFRvIII), which has an in-
frame deletion of exons 2–7 within the EGFR extracellu-
lar domain [16,17]. Clinical trials with EGFR kinase
inhibitors such as gefitinib and erlotinib did not show a
significant benefit on overall survival or progression-free
survival in patients with malignant glioma [4]. Given the
role of this growth factor receptor in gliomagenesis [18],
the failure of EGFR inhibitors in GBM patients was par-
ticularly disappointing. Understanding the molecularmechanism of resistance may provide insight into the
development of alternative strategies to tackle this issue.
Some studies found that tumors with EGFRvIII [7]
and intact PTEN and tumors with low p-Akt levels are
more likely to respond to EGFR inhibitors [19]. Several
investigators have identified loss of the PTEN tumor
suppressor as a resistance factor for EGFR kinase inhibi-
tor therapy [5,20,21]. Vivanco et al. also showed a crit-
ical role of PTEN in downregulation of activated EGFR.
The PI3K/Akt/mTOR pathway is a critical regulator of
tumor cell metabolism, growth, proliferation, and sur-
vival. In malignant gliomas, activity of this signaling net-
work is frequently increased because of receptor tyrosine
kinase over-activity, loss of PTEN tumor suppressor,
and/or mutated oncogenic PI3K subunits [6]. We ob-
served a PTEN-mutant gloma cells showed higher radio-
sensitizing effect of PI103 than that of PTEN-wild type
glioma cells. Our finding also supports the potential and
rationale for PI3K targeting strategy in the treatment of
malignant glioma having PTEN loss.
Attempts to inhibit the PI3K pathway with pan-PI3K in-
hibitors such as LY294002 have not progressed to clinical
use due to concerns over organ toxicity and a lack of se-
lectivity [22,23]. Inhibition of the pathway using rapamycin
resulted in paradoxical activation of Akt through loss of
negative feedback in a subset of patients, which in turn
was related to shorter time-to-progression during postsur-
gical maintenance rapamycin therapy [24]. The limited
single-agent activity of rapamycin analogs in several GBM
trials [25,26] provides a rationale for ongoing clinical trials
with dual PI3K/mTOR inhibitors in GBM. A clinical trial
of a dual PI3K/m-TOR inhibitor, XL765, in combination
with TMZ is currently underway for GBM [27]. Our results
are in line with previous reports since combined treatment
with TMZ and a dual PI3K/m-TOR inhibitor, XL765, has
been successfully tested in glioma cell lines [23,27]. Al-
though rapamycin was a strong inducer of autophagy, it
did not increased cytotoxicity of radiation therpy combined
with temozolomide. In contrast, PI103 which is a dual in-
hibitor of class I PI3K and m-TOR prolonged gammH2AX
foci formation with downregulation of p-DNA-PK,
increased autophagy and increased cytotoxicity of radiation
and temozolomide. We speculated that the impairment of
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Figure 5 Invasion, migration and vasculogenic mimicry formation of U251 glioma cells. The effects of each treatment on invasion,
migration, and vasculogenic mimicry (VM). (A & B) U251 cells invasion/migration was determined by using Modified Boyden chamber assay and
Wound healing assay. Stained cells in representative fields (100×). The number of cells that had invaded and migrated 24 hours after treatment
shown as histogram. Data are presented as the mean ± SD of three experiments. *P < 0.05 versus IR. †P < 0.05 versus IR and TMZ. (C) The ability of
U251 cells to form VM when plated on matrigel was determined in each treatment. Photographs of representative VM formation fields are shown
(200×). (D) The combination treatment of TMZ with PI103 or 17-DMAG or LBH589 resulted in down-regulation of VEGF, MMP-2, and EphA2
expression and up-regulation of E-cadherin expression, by Western blot analysis. β-actin was detected as loading control. (E) The level of EphA2
immunofluorescence is visibly lower in the combination treatment of TMZ with PI103 or 17-DMAG or LBH589 compared to TMZ alone treatment
in U251 cells. Each experiment was repeated three times with similar results.
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Based on our results, we propose dual targeting PI3K/m-
TOR with PI103 as a viable therapeutic strategy which
should be explored to bypass the therapeutic resistance of
GBM.
The data from TCGA for GBM indicate that tumori-
genesis and progression involve multiple molecular ab-
normalities [28]. HSP90, a molecular chaperon, is
essential for the stability and function of many onco-
genic client proteins that are frequently dysregulated in
GBM, such as mutant EGFR, Akt, and p53. Since HSP90
is essential for the function of normal cells as well as
tumor cells, one might be concerned that inhibition of
its functions might not be selective for malignancy. Both
preclinical and clinical observations, however, have
shown that HSP90 inhibitors can be given in vivo at
doses and schedules that exert antitumor activity with-
out causing host toxicity [29]. In addition to counteract-
ing pro-survival signaling, HSP90 inhibitors block cell
motility and invasion by suppressing multiple pro-
invasive and pro-angiogenic cellular processes, such as
MMP-2, VEGF [30] and EphA2 activity [31]. Moreover,
HSP90 can play a role in DSB repair and the activation
of cell cycle check point [32]. Inhibition of multiple sig-
naling circuitries through the abrogation of HSP90 may
be an effective treatment strategy for highly recalcitrant
tumors such as GBM [33-35].
HDAC inhibitors (HDIs) target epigenetic modifica-
tions that interfere with transcriptional regulation and
can induce growth arrest and cell death [36-38]. We pre-
viously reported that HDIs potentiate radiation-induced
cell killing in a panel of human cancer cells through di-
verse mechanism: LBH589 preferentially radiosensitized
human glioma cells that exhibited activated EGFR sig-
naling due to the EGFRVIII mutation. Treatment with
LBH589 led to acetylation of HSP90, which induced
down-regulation of the client oncoproteins EGFR and
decreased levels of p-Akt [39]. LBH589 has also been re-
ported to inhibit angiogenesis [40] and induce apoptosis,
and delay of DNA damage repair in lung cancer cells
with activated EGFR [41]. Srivastava et al. reported that
MS-275 inhibited tumor cell proliferation, angiogenesis,
metastasis and reversing EMT in vivo breast cancer
xenograft model by causing “cadherin switch” and de-
creased expression of VEGF, HIF-1, MMP-2 and MMP-9
[42]. In our results, LBH589 significantly blocked migra-
tion, invasion, and vasculogenic mimicry formation
through the down-regulation of VEGF, MMP-2, EphA2
and up-regulation of E-cadherin in U251 glioma cells.
Given the link between mesenchymal feature and the
progression of GBM, attacking EphA2, VEGF, and
MMP-2 expression by these agents might be a potential
strategy to improve the therapeutic outcome of com-
bined radiotherapy and TMZ for GBM.Conclusions
Taken together, our data suggest that targeting PI3K and
mTOR pathway, ligand-independent modulation using
an inhibitor of HSP90, or epigenetic modulation through
inhibition of HDAC could be potential strategies to
improve the therapeutic outcome of GBM. Increased
radiosensitizing effects of combination therapy with
TMZ were associated with impairment of DNA damage
repair, the induction of apoptosis or autophagy, and the
reversion of EMT. Since the biology of malignant glioma
involves a complex network of interconnected signaling
pathways resulting in cell growth, survival and the
invasive phenotype, careful preclinical interrogation is
necessary to determine optimal treatment combinations.
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